Abstract 127P
Background
Pancreatic ductal adenocarcinoma (PDAC) has poor prognosis due to its late detection, high stromal content, and high relapse rate. Immunosuppressive tumor microenvironment creates a major challenge for PDAC immunotherapy requiring novel therapeutic approaches. Ad5/3-E2F-d24-vIL2 (vIL2-virus) is an engineered oncolytic adenovirus (OAd) encoding a variant IL-2 cytokine. vIL-2 expression leads to preferential stimulation of natural killer cell and effector lymphocyte expansion over T regulatory cell proliferation. We propose to combine vIL2-virus to nab-paclitaxel, gemcitabine, and anti-PD-L1 to formulate an effective immunotherapeutic treatment for the traditionally therapy-resistant PDAC.
Methods
PDAC cell lines treated with vIL2-virus, normal IL-2 virus, and unarmed virus were studied in mono- and co-cultures with macrophages and fibroblasts with flow cytometry profiling. Ex vivo experiments with real time cell killing assays were performed with clinical PDAC samples with concurrent flow cytometric and cytokine analysis. In vivo antitumor efficacy and safety of the combination were tested using an immunocompetent hamster model.
Results
Increasing doses of gemcitabine, paclitaxel, and virotherapies led to increased PD-L1 expression on PDAC cells. Different OAds showed lower levels of PD-L1 upregulation on cancer cells when co-cultured with macrophages or fibroblasts, while macrophages and fibroblasts expressed PD-L1 considerably more than cancer cells after IFN-gamma stimulation. Macrophages upregulated PD-L1 and PD-L2 only around virus producing normal human IL-2. Experiments with clinical PDAC samples showed efficient cancer cell killing and cytotoxic immune cell changes by the combination therapy. In vivo, the triple therapy showed significantly improved tumor growth control and survival compared to chemotherapy with anti-PD-L1 or chemotherapy alone. Moreover, animals cured by the triple treatment showed increased resistance to tumor re-challenge.
Conclusions
A combination of vIL2-virus, chemotherapy, and anti-PD-L1 is a promising strategy to overcome therapeutic limitations and effectively improve outcome in patients with PDAC.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
J. Clubb, J. Santos: Financial Interests, Personal, Full or part-time Employment, Employee of TILT Biotherapeutics: TILT Biotherapeutics Ltd; Financial Interests, Personal, Stocks/Shares: TILT Biotherapeutics Ltd. L. Haybout: Financial Interests, Personal, Full or part-time Employment, Employee of TILT Biotherapeutics: TILT Biotherapeutics Ltd. D.C.A. Quixabeira: Financial Interests, Institutional, Full or part-time Employment: TILT Biotherapeutics. V. Cervera-Carrascon: Financial Interests, Personal, Full or part-time Employment: TILT Biotherapeutics Ltd; Financial Interests, Personal, Stocks/Shares: TILT Biotherapeutics Ltd. A. Hemminki: Financial Interests, Personal, Financially compensated role: TILT Biotherapeutics Ltd; Financial Interests, Personal, Stocks/Shares: TILT Biotherapeutics Ltd, Circio Holdings ASA; Financial Interests, Personal, Stocks or ownership: Aeruginosa Oy; Non-Financial Interests, Institutional, Research Grant: Helsinki University Hospital Research funds, Cancer Foundation Finland, Jane and Aatos Erkko Foundation, Red Cross Blood Service, Sigrid Juselius Finland, European Commission. All other authors have declared no conflicts of interest.
Resources from the same session
43P - Machine learning radiomics based on CT to predict response to lenvatinib plus tislelizumab based therapy for unresectable hepatocellular carcinoma
Presenter: Gang Chen
Session: Poster Display session
Resources:
Abstract
44P - Machine learning-based prediction of survival in patients with metastatic renal cell carcinoma receiving first-line immunotherapy
Presenter: Ahmed Elgebaly
Session: Poster Display session
Resources:
Abstract
45P - Gut microbiome signatures for exploring the correlation between gut microbiome and immune therapy response using machine learning approach
Presenter: Han Li
Session: Poster Display session
Resources:
Abstract
46P - Abnormal gut microbiota may cause PD-1 inhibitor-related cardiotoxicity via suppressing regulatory T cells
Presenter: Zeeshan Afzal
Session: Poster Display session
Resources:
Abstract
47P - Correlation of clinical, genetic and transcriptomic traits with PD-L1 positivity in TNBC patients
Presenter: Anita Semertzidou
Session: Poster Display session
Resources:
Abstract
48P - The A2AR antagonist inupadenant promotes humoral responses in preclinical models
Presenter: Paola Tieppo
Session: Poster Display session
Resources:
Abstract
49P - Highly potent novel armoured IL13Ra2 CAR T cell targeting glioblastoma
Presenter: Maurizio Mangolini
Session: Poster Display session
Resources:
Abstract
50P - Phase I trial of P-MUC1C-ALLO1 allogeneic CAR-T cells in advanced epithelial malignancies
Presenter: David Oh
Session: Poster Display session
Resources:
Abstract
51P - Unlocking CAR-T cell potential: Lipid metabolites in overcoming exhaustion in ovarian cancer
Presenter: Xiangyu Chang
Session: Poster Display session
Resources:
Abstract
52P - Tumor-targeted cytokine release by genetically-engineered myeloid cells rescues CAR-T activity and engages endogenous T cells against high-grade glioma in mouse models
Presenter: Federico Rossari
Session: Poster Display session
Resources:
Abstract